To test the generality of the synergy, we knocked down CDK1/CDK4/CDK6 in cell lines derived from different cancer types, including A549 (non-small cell lung cancer) and MCF7 (ER+ breast cancer), and treated them with metformin. Here, CDK6 is linked to non-small cell lung carcinoma.